
Amy Colson, MD, MPH, discusses data from the MK-8591A-052 trial that showed that switching to doravirine/islatravir maintained durable virologic suppression with efficacy and safety comparable to continuing bictegravir/emtricitabine/tenofovir alafenamide.


























